Literature DB >> 12552113

Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice.

R W Gelling1, X Q Du, D S Dichmann, J Romer, H Huang, L Cui, S Obici, B Tang, J J Holst, C Fledelius, P B Johansen, L Rossetti, L A Jelicks, P Serup, E Nishimura, M J Charron.   

Abstract

Glucagon, the counter-regulatory hormone to insulin, is secreted from pancreatic alpha cells in response to low blood glucose. To examine the role of glucagon in glucose homeostasis, mice were generated with a null mutation of the glucagon receptor (Gcgr(-/-)). These mice display lower blood glucose levels throughout the day and improved glucose tolerance but similar insulin levels compared with control animals. Gcgr(-/-) mice displayed supraphysiological glucagon levels associated with postnatal enlargement of the pancreas and hyperplasia of islets due predominantly to alpha cell, and to a lesser extent, delta cell proliferation. In addition, increased proglucagon expression and processing resulted in increased pancreatic glucogen-like peptide 1 (GLP-1) (1-37) and GLP-1 amide (1-36 amide) content and a 3- to 10-fold increase in circulating GLP-1 amide. Gcgr(-/-) mice also displayed reduced adiposity and leptin levels but normal body weight, food intake, and energy expenditure. These data indicate that glucagon is essential for maintenance of normal glycemia and postnatal regulation of islet and alpha and delta cell numbers. Furthermore, the lean phenotype of Gcgr(-/-) mice suggests glucagon action may be involved in the regulation of whole body composition.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12552113      PMCID: PMC298791          DOI: 10.1073/pnas.0237106100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

Review 1.  Proteolytic processing in the secretory pathway.

Authors:  A Zhou; G Webb; X Zhu; D F Steiner
Journal:  J Biol Chem       Date:  1999-07-23       Impact factor: 5.157

Review 2.  The glucagon-like peptides.

Authors:  T J Kieffer; J F Habener
Journal:  Endocr Rev       Date:  1999-12       Impact factor: 19.871

3.  Kinetic and functional characterization of 1,4-dideoxy-1, 4-imino-d-arabinitol: a potent inhibitor of glycogen phosphorylase with anti-hyperglyceamic effect in ob/ob mice.

Authors:  K Fosgerau; N Westergaard; B Quistorff; N Grunnet; M Kristiansen; K Lundgren
Journal:  Arch Biochem Biophys       Date:  2000-08-15       Impact factor: 4.013

Review 4.  Obesity, diabetes and the central nervous system.

Authors:  D Porte; R J Seeley; S C Woods; D G Baskin; D P Figlewicz; M W Schwartz
Journal:  Diabetologia       Date:  1998-08       Impact factor: 10.122

5.  Discovery and structure-activity relationship of the first non-peptide competitive human glucagon receptor antagonists.

Authors:  P Madsen; L B Knudsen; F C Wiberg; R D Carr
Journal:  J Med Chem       Date:  1998-12-17       Impact factor: 7.446

6.  Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2.

Authors:  M Furuta; H Yano; A Zhou; Y Rouillé; J J Holst; R Carroll; M Ravazzola; L Orci; H Furuta; D F Steiner
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

7.  Glycemic control in mice with targeted disruption of the glucagon receptor gene.

Authors:  Janice C Parker; Kim M Andrews; Melanie R Allen; Jeffrey L Stock; John D McNeish
Journal:  Biochem Biophys Res Commun       Date:  2002-01-18       Impact factor: 3.575

8.  Glucagon replacement via micro-osmotic pump corrects hypoglycemia and alpha-cell hyperplasia in prohormone convertase 2 knockout mice.

Authors:  Gene C Webb; Murtaza S Akbar; Chongjian Zhao; Hewson H Swift; Donald F Steiner
Journal:  Diabetes       Date:  2002-02       Impact factor: 9.461

9.  Incomplete processing of proinsulin to insulin accompanied by elevation of Des-31,32 proinsulin intermediates in islets of mice lacking active PC2.

Authors:  M Furuta; R Carroll; S Martin; H H Swift; M Ravazzola; L Orci; D F Steiner
Journal:  J Biol Chem       Date:  1998-02-06       Impact factor: 5.157

10.  A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation.

Authors:  K Paz; R Hemi; D LeRoith; A Karasik; E Elhanany; H Kanety; Y Zick
Journal:  J Biol Chem       Date:  1997-11-21       Impact factor: 5.157

View more
  218 in total

1.  Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes.

Authors:  Emilie Bahne; Emily W L Sun; Richard L Young; Morten Hansen; David P Sonne; Jakob S Hansen; Ulrich Rohde; Alice P Liou; Margaret L Jackson; Dayan de Fontgalland; Philippa Rabbitt; Paul Hollington; Luigi Sposato; Steven Due; David A Wattchow; Jens F Rehfeld; Jens J Holst; Damien J Keating; Tina Vilsbøll; Filip K Knop
Journal:  JCI Insight       Date:  2018-12-06

Review 2.  Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes.

Authors:  Philip E Cryer
Journal:  Endocrinology       Date:  2011-12-13       Impact factor: 4.736

3.  Hypoglycemia, hyperglucagonemia, and fetoplacental defects in glucagon receptor knockout mice: a role for glucagon action in pregnancy maintenance.

Authors:  Sophia Ouhilal; Patricia Vuguin; Lingguang Cui; Xiu-Quan Du; Richard W Gelling; Sandra E Reznik; Robert Russell; Albert F Parlow; Clara Karpovsky; Nanette Santoro; Maureen J Charron
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-12-13       Impact factor: 4.310

4.  Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice.

Authors:  Y Takeda; Y Fujita; J Honjo; T Yanagimachi; H Sakagami; Y Takiyama; Y Makino; A Abiko; T J Kieffer; M Haneda
Journal:  Diabetologia       Date:  2011-11-10       Impact factor: 10.122

5.  Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors.

Authors:  Kyle W Sloop; Julia Xiao-Chun Cao; Angela M Siesky; Hong Yan Zhang; Diane M Bodenmiller; Amy L Cox; Steven J Jacobs; Julie S Moyers; Rebecca A Owens; Aaron D Showalter; Martin B Brenner; Achim Raap; Jesper Gromada; Brian R Berridge; David K B Monteith; Niels Porksen; Robert A McKay; Brett P Monia; Sanjay Bhanot; Lynnetta M Watts; M Dodson Michael
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

Review 6.  Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover.

Authors:  Roger H Unger; Alan D Cherrington
Journal:  J Clin Invest       Date:  2012-01-03       Impact factor: 14.808

Review 7.  Adult pancreatic alpha-cells: a new source of cells for beta-cell regeneration.

Authors:  Cheng-Ho Chung; Fred Levine
Journal:  Rev Diabet Stud       Date:  2010-08-10

Review 8.  Paracrine signaling in islet function and survival.

Authors:  Sean M Hartig; Aaron R Cox
Journal:  J Mol Med (Berl)       Date:  2020-02-17       Impact factor: 4.599

9.  Evidence for a regulatory role of Cullin-RING E3 ubiquitin ligase 7 in insulin signaling.

Authors:  Florian Scheufele; Benjamin Wolf; Michael Kruse; Thomas Hartmann; Justine Lempart; Susanne Mühlich; Andreas F H Pfeiffer; Loren J Field; Maureen J Charron; Zhen-Qiang Pan; Stefan Engelhardt; Antonio Sarikas
Journal:  Cell Signal       Date:  2013-11-09       Impact factor: 4.315

10.  Glucagon receptor gene mutations with hyperglucagonemia but without the glucagonoma syndrome.

Authors:  Helen C Miller; Mark Kidd; Irvin M Modlin; Patrizia Cohen; Roberto Dina; Panagiotis Drymousis; Panagiotis Vlavianos; Günter Klöppel; Andrea Frilling
Journal:  World J Gastrointest Surg       Date:  2015-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.